FDA approves Covidien's generic Actiq
The FDA approved Covidien's version of Actiq, a pain drug from Cephalon used in cancer patients who do not respond to other drugs. Covidien plans to sell six doses of the drug, fentanyl citrate, early next year.
Forbes
| 10/30
This story published in FDLI SmartBrief on 11/02/2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|